Show simple item record

dc.contributor.authorRestrepo, Marcos I.
dc.contributor.authorBabu, Bettina L.
dc.contributor.authorReyes, Luis F.
dc.contributor.authorChalmers, James D.
dc.contributor.authorSoni, Nilam J.
dc.contributor.authorSibila, Oriol
dc.contributor.authorFaverio, Paola
dc.contributor.authorCilloniz, Catia
dc.contributor.authorRodriguez Cintron, William
dc.contributor.authorAliberti, Stefano
dc.date.accessioned2020-06-02T13:43:29Z
dc.date.available2020-06-02T13:43:29Z
dc.date.issued2018-06-06
dc.identifier.citationRestrepo MI, Babu BL, Reyes LF, et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J 2018; 52: 1701190 [https://doi.org/10.1183/13993003.01190-2017].es_CO
dc.identifier.issn0903-1936
dc.identifier.otherhttps://erj.ersjournals.com/content/52/2/1701190.long
dc.identifier.otherhttps://erj.ersjournals.com/content/erj/52/2/1701190.full.pdf
dc.identifier.otherhttps://pubmed.ncbi.nlm.nih.gov/29976651/
dc.identifier.urihttp://hdl.handle.net/10818/41419
dc.description14 páginases_CO
dc.description.abstractPseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patientseng
dc.formatapplication/pdfes_CO
dc.language.isoenges_CO
dc.publisherEuropean Respiratory Journales_CO
dc.relation.ispartofseriesEur Respir J 2018; 52: 1701190
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceinstname:Universidad de La Sabanaes_CO
dc.sourcereponame:Intellectum Repositorio Universidad de La Sabanaes_CO
dc.titleBurden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patientses_CO
dc.title.alternativeCarga y factores de riesgo para la neumonía adquirida en la comunidad de Pseudomonas aeruginosa : un estudio multinacional de prevalencia puntual de pacientes hospitalizadoses_CO
dc.typearticlees_CO
dc.type.hasVersionpublishedVersiones_CO
dc.rights.accessRightsopenAccesses_CO
dc.identifier.doi10.1183 / 13993003.01190-2017


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcept where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International